Alternative Vismodegib Dosing Regimen for Patients with Basal Cell Carcinoma

Main Article Content

Timothy Jay Orlowski
Callie Hill
Natalie Garcia
Victoria Jiminez
Carlton Phillips

Keywords

Pharmacology, Vismodegib, Basal cell carcinoma, Skin cancer

References

1. Proctor AE, Thompson LA, O'Bryant CL. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma. Ann Pharmacother. 2014;48(1):99-106.

2. Sekulic A, Migden MR, Lewis K, et al. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015;72(6):1021-6.e8.

3. Dréno B, Kunstfeld R, Hauschild A, et al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol. 2017;18(3):404-412.

4. Villani A, Costa C, Fabbrocini G, et al. Drug holiday regimen for vismodegib treatment in patients with multiple primary basal cell carcinomas. Dermatol Ther. 2020;33(4):e13707.

5. Valenzuela-Oñate CA, Magdaleno-Tapial J, Garcia-Legaz Martínez M, et al. Drug holiday approach for Vismodegib treatment in patients with nevoid basal cell carcinoma syndrome: Three cases from real clinical practice. Dermatol Ther. 2020;33(4):e13540.

6. Wong C, Poblete-Lopez C, Vidimos A. Comparison of daily dosing versus Monday through Friday dosing of vismodegib for locally advanced basal cell carcinoma and basal cell nevus syndrome: A retrospective case series. J Am Acad Dermatol. 2020;82(6):1539-1542.

Article Sidebar

PDF
Published
Sep 15, 2023
DOI https://doi.org/10.25251/skin.7.5.5

Article Details

How to Cite
Orlowski, T. J., Hill, C., Garcia, N., Jiminez, V., & Phillips, C. (2023). Alternative Vismodegib Dosing Regimen for Patients with Basal Cell Carcinoma. SKIN The Journal of Cutaneous Medicine, 7(5), 1001–1004. https://doi.org/10.25251/skin.7.5.5
Issue
Vol. 7 No. 5 (2023): September 2023 Issue
Section
Research Letters
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 > >>